Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 3/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221477 | 0.87 | ITGA4 (0.60) | ITGA4ITGB7CTSLCTSKMEN1 | |
| SCHEMBL19871011 | 0.87 | PPARG (0.50) | ITGA4ITGB7CTSLMEN1KMT2A | |
| SCHEMBL1221478 | 0.87 | ITGA4 (0.60) | ITGA4ITGB7CTSLCTSKMEN1 | |
| SCHEMBL8433969 | 0.84 | CTSL (0.62) | ITGA4ITGB7CTSLCTSKP2RX7 | |
| SCHEMBL8433892 | 0.84 | CTSL (0.62) | ITGA4ITGB7CTSLCTSKP2RX7 | |
| SCHEMBL8436808 | 0.84 | CTSL (0.62) | ITGA4ITGB7CTSLCTSKP2RX7 | |
| SCHEMBL25922264 | 0.84 | PPARG (0.56) | CTSLMEN1KMT2A | |
| SCHEMBL7327394 | 0.84 | CTSL (0.57) | ITGA4ITGB7CTSLCTSKP2RX7 | |
| SCHEMBL10793551 | 0.84 | CTSL (0.57) | ITGA4ITGB7CTSLCTSKP2RX7 | |
| SCHEMBL1715348 | 0.84 | CTSL (0.57) | ITGA4ITGB7CTSLCTSKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044350-A1 | THERAPEUTIC CYCLIC COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044350-A1 | THERAPEUTIC CYCLIC COMPOUNDS AS IMMUNOMODULATORS | PDCD1LG2, PDCD1, CD274 | ITGA4 4478/4885ITGB7 3225/4885CTSL 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.